中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

35 records (took 0.134 seconds)

    COMPSTATIN ANALOGS FOR TREATMENT OF NEUROPATHIC PAIN
    22.
    发明申请
    COMPSTATIN ANALOGS FOR TREATMENT OF NEUROPATHIC PAIN 审中-公开
    用于治疗神经性疼痛的COMPSTATIN模拟物

    公开(公告)号：US20130203678A1

    公开(公告)日：2013-08-08

    申请号：US13805538

    申请日：2012-06-08

    Applicant: Cedric Francois ,  Pascal Deschatelets

    Inventor： Cedric Francois ,  Pascal Deschatelets

    IPC: A61K38/10 ,  A61K45/06 ,  A61K38/12

    Abstract: In some aspects, the present invention provides methods of treating a subject in need of treatment for neuropathic pain, the method comprising administering a compstatin analog to the subject. In some embodiments, the compstatin analog is administered parenterally, e.g., intravenously.

    Abstract translation: 在一些方面，本发明提供治疗需要治疗神经性疼痛的受试者的方法，所述方法包括向受试者施用化合物抑制素类似物。 在一些实施方案中，所述化合物抑制素类似物肠胃外给药，例如静脉内给药。

    Viral Complement Control Proteins for Eye Disorders
    23.
    发明申请
    Viral Complement Control Proteins for Eye Disorders 审中-公开
    用于眼部疾病的病毒补体控制蛋白

    公开(公告)号：US20130072442A1

    公开(公告)日：2013-03-21

    申请号：US13251818

    申请日：2011-10-03

    Applicant: Pascal Deschatelets ,  Paul Olson ,  Cedric Francois

    Inventor： Pascal Deschatelets ,  Paul Olson ,  Cedric Francois

    IPC: A61K38/16

    CPC classification number: A61K38/162 ,  A61K9/0051 ,  A61K38/17

    Abstract: The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.

    Abstract translation: 本发明提供用于治疗和/或预防年龄相关性黄斑变性和涉及黄斑变性或脉络膜新生血管形成，眼部炎症或其任何组合的其它病症的组合物和方法。 某些组合物包含痘病毒补体对照蛋白或其补体结合片段或变体。 其他组合物包含与结合存在于细胞或非细胞分子实体的表面或其表面上的组分连接的部分的痘病毒补体对照蛋白，例如存在于患有年龄相关性黄斑的风险的患者的眼睛中的组分 变性或相关病症或脉络膜新生血管形成，眼部炎症或这些的任何组合。 某些方法包括向受试者施用痘病毒补体对照蛋白或补体结合片段或其变体。

    Viral complement control proteins for eye disorders
    26.
    发明授权
    Viral complement control proteins for eye disorders 失效
    用于眼睛疾病的病毒补体对照蛋白

    公开(公告)号：US07947267B2

    公开(公告)日：2011-05-24

    申请号：US11247886

    申请日：2005-10-08

    Applicant: Cedric Francois ,  Pascal Deschatelets ,  Paul Olson

    Inventor： Cedric Francois ,  Pascal Deschatelets ,  Paul Olson

    IPC: A61K35/00 ,  C07K5/00

    CPC classification number: A61K38/162 ,  C07K14/005 ,  C07K2319/33 ,  C12N2710/24122

    Abstract: The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.

    Abstract translation: 本发明提供用于治疗和/或预防年龄相关性黄斑变性和涉及黄斑变性或脉络膜新生血管形成的其它病症的组合物和方法。 某些组合物包含痘病毒补体对照蛋白或其补体结合片段或变体。 其他组合物包含与结合存在于细胞或非细胞分子实体的表面或其表面上的组分连接的部分的痘病毒补体对照蛋白，例如存在于患有年龄相关性黄斑的风险的患者的眼睛中的组分 变性或相关病症或脉络膜新生血管形成。 某些方法包括向受试者施用痘病毒补体对照蛋白或补体结合片段或其变体。

    Injectable Combination Therapy for Eye Disorders
    27.
    发明申请
    Injectable Combination Therapy for Eye Disorders 审中-公开
    注射组合治疗眼疾

    公开(公告)号：US20090220572A1

    公开(公告)日：2009-09-03

    申请号：US12161410

    申请日：2007-01-19

    Applicant: Pascal Deschatelets ,  Paul Olson ,  Cedric Francois

    Inventor： Pascal Deschatelets ,  Paul Olson ,  Cedric Francois

    IPC: A61K9/127 ,  A61K9/00 ,  A61K39/395 ,  A61K31/7052 ,  A61K38/16 ,  A61K38/02 ,  A61K38/10 ,  A61K9/14 ,  A61P27/02

    CPC classification number: C07K7/08 ,  A61F9/0008 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/0051 ,  A61K31/00 ,  A61K31/7105 ,  A61K38/00 ,  A61K38/08 ,  A61K38/10 ,  A61K38/12 ,  A61K38/17 ,  A61K39/3955 ,  A61K49/0008 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/28 ,  C07K2319/01 ,  G01N33/6872 ,  G01N2333/4704 ,  G01N2500/04 ,  G01N2500/20

    Abstract: The present invention provides composition, methods, and articles of manufacture for treating an eye disorder, e.g., a disorder characterized by macular degeneration, choroidal neovascularization, or retinal neovascularization. One method of the invention comprises the step of: administering first and second therapeutic agents to the subject's eye in a single procedure, wherein the first therapeutic agent provides rapid improvement in the condition of the subject's eye and the second therapeutic agent is administered as a sustained release formulation of the second therapeutic agent. For example, the first and second therapeutic agents are administered by intravitreal injection. The first therapeutic agent may be dissolved in a liquid medium located in the syringe and the sustained formulation of the second therapeutic agent may comprise an ocular implant or plurality of particles located in the needle. The therapeutic agents may be selected from the group consisting of angiogenesis inhibitors and complement inhibitors.

    Abstract translation: 本发明提供用于治疗眼睛疾病的组合物，方法和制品，例如以黄斑变性，脉络膜新生血管形成或视网膜新生血管形成为特征的病症。 本发明的一种方法包括以下步骤：在单一程序中向受检者的眼睛施用第一和第二治疗剂，其中第一治疗剂提供对象眼睛状况的快速改善，而第二治疗剂作为持续的 释放第二治疗剂的制剂。 例如，第一和第二治疗剂通过玻璃体内注射给药。 第一治疗剂可以溶解在位于注射器中的液体介质中，并且第二治疗剂的持续制剂可以包括眼部植入物或位于针中的多个颗粒。 治疗剂可以选自血管生成抑制剂和补体抑制剂。

    Compositions and methods for treatment of macular degeneration and related conditions
    28.
    发明申请
    Compositions and methods for treatment of macular degeneration and related conditions 审中-公开
    用于治疗黄斑变性和相关病症的组合物和方法

    公开(公告)号：US20090117171A1

    公开(公告)日：2009-05-07

    申请号：US11375587

    申请日：2006-03-13

    Applicant: Cedric Francois ,  Pascal Deschatelets ,  Paul Olson

    Inventor： Cedric Francois ,  Pascal Deschatelets ,  Paul Olson

    IPC: A61K9/00 ,  A61K31/195 ,  A61P27/02

    CPC classification number: A61K38/005 ,  A61L27/227

    Abstract: The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or ocular inflammation. The methods comprise administering a composition comprising a compound that is an antagonist of a G protein coupled receptor, e.g., the C5a receptor, to a subject in need of treatment or prevention of age-related macular degeneration or another condition involving macular degeneration or ocular neovascularization. The invention provides compositions comprising a compound that is an antagonist of a G protein coupled receptor linked either directly or indirectly to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization.

    Abstract translation: 本发明提供用于治疗和/或预防年龄相关性黄斑变性和涉及黄斑变性，眼新生血管形成或眼部炎症的其它病症的方法和组合物。 所述方法包括向需要治疗或预防年龄相关性黄斑变性的受试者施用包含作为G蛋白偶联受体的拮抗剂（例如，C5a受体）的化合物的组合物或涉及黄斑变性或眼新生血管形成的另一种病症 。 本发明提供了包含化合物的组合物，其是G蛋白偶联受体的拮抗剂，其直接或间接地连接到与存在于细胞或非细胞分子实体中或其表面上的组分结合的部分，例如存在于 患有年龄相关性黄斑变性或相关病症或脉络膜新血管形成危险的患者的眼睛。

    Modifying macrophage phenotype for treatment of disease
    29.
    发明申请
    Modifying macrophage phenotype for treatment of disease 审中-公开
    改变巨噬细胞表型治疗疾病

    公开(公告)号：US20060257359A1

    公开(公告)日：2006-11-16

    申请号：US11364670

    申请日：2006-02-28

    Applicant: Cedric Francois ,  Pascal Deschatelets ,  Paul Olson

    Inventor： Cedric Francois ,  Pascal Deschatelets ,  Paul Olson

    IPC: A61K38/21 ,  A61K38/20 ,  A61K38/19

    CPC classification number: A61K38/195 ,  A61K38/00 ,  A61K38/1774 ,  A61K45/06

    Abstract: The present invention provides compositions and methods for modulating one or more phenotypes of a macrophage-related cell, e.g., a macrophage. The invention further provides methods of treating disease by modulating macrophage phenotype. Representative phenotypes include pro-inflammatory, anti-inflammatory, immunogenic, tolerogenic, tissue-destructive, tissue restorative, cytotoxic, migratory, bone-resorbing, pro-angiogenic, anti-angiogenic, suppressor, antigen presentation, or phagocytic. Representative diseases include atherosclerosis, arthritis, and multiple sclerosis.

    Abstract translation: 本发明提供用于调节巨噬细胞相关细胞例如巨噬细胞的一种或多种表型的组合物和方法。 本发明还提供了通过调节巨噬细胞表型来治疗疾病的方法。 代表性表型包括促炎症，抗炎，免疫原性，耐受性，组织破坏性，组织修复，细胞毒性，迁移性，骨吸收，促血管生成，抗血管生成，抑制，抗原呈递或吞噬。 代表性疾病包括动脉粥样硬化，关节炎和多发性硬化。

    Photovoltaic Device With Trimetaspheres
    30.
    发明申请
    Photovoltaic Device With Trimetaspheres 审中-公开
    具有三角锥的光伏器件

    公开(公告)号：US20070295395A1

    公开(公告)日：2007-12-27

    申请号：US10594073

    申请日：2005-03-25

    Applicant: J. Phillips ,  Daniela Topasna ,  Steven Stevenson ,  Pascal Deschatelets ,  Bryan Koene

    Inventor： J. Phillips ,  Daniela Topasna ,  Steven Stevenson ,  Pascal Deschatelets ,  Bryan Koene

    IPC: H01L31/04 ,  H01L31/0256 ,  H01L51/00

    CPC classification number: H01L51/4253 ,  B82Y10/00 ,  B82Y30/00 ,  B82Y40/00 ,  C01B32/15 ,  C01B32/152 ,  H01L51/0036 ,  H01L51/0037 ,  H01L51/0046 ,  H01L51/0077 ,  H01L51/0089 ,  H01L51/424 ,  Y02E10/549

    Abstract: An exemplary photovoltaic device for conversion of an incident wavelength of electromagnetic radiation to electricity has an absorber of incident wavelength of electromagnetic radiation, a trimetasphere in electron transferring contact with the absorber, an anode in electrical contact with the trimetasphere, and a cathode in electrical contact with the absorber. The absorber and trimetasphere can be arranged as a heterojunction or a blended junction. An exemplary electrical circuit has an absorber of incident electromagnetic radiation, a trimetasphere-containing material in electron transferring contact with the absorber, an anode, a cathode and a current path from the anode to the cathode. An exemplary method of converting incident electromagnetic radiation to an electrical signal using a trimetasphere-containing material is also disclosed.

    Abstract translation: 用于将电磁辐射的入射波长转换为电的示例性光伏器件具有电磁辐射的入射波长的吸收体，与吸收体的电子转移接触的三角肌，与三角肌电接触的阳极和电接触的阴极 与吸收器。 吸收体和三角突耳可以排列成异质结或混合结。 示例性电路具有入射电磁辐射的吸收体，与吸收体电子转移接触的含三聚甲醛的材料，阳极，阴极和从阳极到阴极的电流路径。 还公开了一种用入射电磁辐射将电子信号转换为电信号的示例性方法。

Patent Agency Ranking